Sandra M. Swain, MD, the current president of American Society of Clinical Oncology (ASCO), holds an international reputation as one of the America’s Leading Experts on Adjuvant Chemotherapy & Breast Cancer (Breast Neoplasm) and the leading authority both in the emergent field of inflammatory breast cancer treatment and in the treatment of early breast cancer with 28 years of medical experience and practice in Medical Oncology. After her keynote speech under the theme of “The treatment of HER2 positive breast cancer” in Chinese Society of Clinical Oncology (CSCO) 2012 conference, Chinese Clinical Oncology (CCO) was honored to have Dr. Swain to share her opinions on Chinese oncology study and her expectations for our young generation to shoulder the future Chinese oncology study.
Dr. Sandra M. Swain